Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA Congress
- Key presentations for BION-1301 at the ISN World Congress of Nephrology 2021 in April include Gd-IgA1 biomarker data in healthy volunteers from Parts 1 and Part 2 of the ongoing phase 1 study of BION-1301, as well as data from the phase 1 IV to SC bioavailability study in healthy volunteers
- Small subset of BION-1301 interim IgA nephropathy patient data to be reported from Part 3 of the ongoing phase 1 study in an oral presentation at the 58th ERA-EDTA Congress in June
VANCOUVER, British Columbia and SEATTLE, March 30, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming data presentations at the ISN World Congress of Nephrology 2021 from April 15 – 19, 2021 and the 58th ERA-EDTA Congress from June 5 – 8, 2021.
The following abstracts will be presented as poster presentations at the ISN World Congress of Nephrology 2021:
Atrasentan
| Abstract WCN21-0848 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study) |
| Author: | Hiddo J. L. Heerspink, University Medical Center Groningen, Groningen, Netherlands |
| Abstract WCN21-0717 | Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study) |
| Author: | Marianne Camargo, M.D. |
| Abstract WCN21-0358 | Selective ETA Antagonist Atrasentan, Rapidly Reduces Albuminuria and Downregulates Intra-renal Pro-Inflammatory and Pro-Fibrotic Transcriptional Networks in the g-ddY Mouse Model of Spontaneous IgA Nephropathy |
| Author: | Andrew King, D.V.M., PhD |
| Abstract WCN21-0398 | Human Renal Mesangial Cell Activation Induced by Endothelin-1 or IgA Nephropathy Patient Immune Derived Complexes is Blocked by Selective ETA Antagonist Atrasentan |
| Author: | Jennifer Cox, Ph.D. |
BION-1301
| Abstract WCN21-0706 | A Phase 1, Open Label, Randomized, Single Dose, Parallel Group Safety and Bioavailability Study of BION-1301 Administered by Intravenous (IV) and Subcutaneous (SC) Routes |
| Author: | Jeannette Lo, Ph.D. |
CHK-336
| Abstract WCN21-0612 | Discovery of CHK-336: A First-in-Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Hyperoxaluria |
| Author: | Jennifer Cox, Ph.D. |
The following abstract was selected for oral presentation at the 58th ERA-EDTA Congress:
| Presentation ID FC040 | Interim Results of Phase 1 and 2 Trials to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of BION-1301 in Patients with IgA Nephropathy |
| Author: | Jonathan Barratt, Ph.D., F.R.C.P, University of Leicester & Leicester General Hospital |
| Session: | Treatment & outcome of glomerulonephritis |
The following abstracts will be presented as mini-oral (poster) presentations at the 58th ERA-EDTA Congress:
Atrasentan
| Abstract ID 1547 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study) |
| Author: | Hiddo J. L. Heerspink, University Medical Center Groningen, Groningen, Netherlands |
BION-1301
| Abstract ID 1024 | Design of a Phase 1, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA Nephropathy (ADU-CL-19) and A Multicenter, Open-Label Extension (OLE) Study for Patients with Immunoglobulin A Nephropathy (IgAN) Who Participated in A Prior Clinical Study of BION-1301 (ADU-CL-24) |
| Author: | Jonathan Barratt, Ph.D., F.R.C.P, University of Leicester & Leicester General Hospital |
For more information on these and other abstracts, please visit the and websites.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an investigational oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit .
Cautionary Note on Forward-Looking Statements
Certain of the statements made in this press release are forward looking, including those relating to Chinook’s business, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding timing of initiation and results of clinical trials. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, including initiation of clinical trials, whether results of early clinical trials or preclinical studies will be indicative of the results of future trials, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that may be more advanced or have greater resources than we do, our ability to obtain and adequately protect intellectual property rights for our product candidates, whether we receive proceeds, if any, related to the CVRs and are able to distribute any of those proceeds to CVR holders, and the effects of COVID-19 on our clinical programs and business operations. Many of these risks are described in greater detail in our filings with the SEC. Any forward-looking statements in this press release speak only as of the date of this press release. Chinook assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Noopur Liffick
Vice President, Investor Relations & Corporate Communications
